medigraphic.com
ISSN 1870-2821 (Print)
Organo Oficial de la Asociación Mexicana de Mastología

2020, Number 3

<< Back Next >>

Rev Mex Mastol 2020; 10 (3)

Epigenetics opportunities as an approach to breast cancer treatment. Epi-pharmaceuticals for breast cancer

Macías Pérez ME, Rodríguez-Fonseca RA, Mera JE, Hernández RM

Language: Spanish
References: 18
Page: 93-97
PDF size: 215.42 Kb.


ABSTRACT

Breast cancer represents 16% of all female cancers in the world, and the majorities (69%) of deaths from this cause are registered in developing countries. According to WHO, each year in the world, 1.38 million new cases appear, and 458 thousand people die. It is the second leading cause of death in Mexican women over 20 years old. The knowledge of omic sciences and new levels of organization in gene expression, such as epigenetics, allow to propose new treatment strategies in breast cancer patients, to generate a personalized treatment specific to the tumor, modulating with a single treatment multiple signaling pathways involved in key processes for tumor survival, although this may be promising, it also raises different views on the adverse effects and drug interactions of epigenetic drugs. The purpose of this review is to identify the lessons learned in the breast cancer epigenetic treatment. The main epigenetic treatments for clinical use, the adverse aspects identified and the opportunity to improve the therapeutic approach with epigenetic drugs.


REFERENCES

  1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948.

  2. Corben AD. Pathology of invasive breast disease. Surg Clin North Am. 2013; 93 (2): 363-392.

  3. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019; 321 (3): 288-300.

  4. Loibl S, Gianni L. HER2-positive breast cancer. Breast Cancer. 2017; 389 (10087): P2415-2429.

  5. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology. 2013; 31: 3997-4013.

  6. Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery: from reality to dreams. Clinical Epigenetics. 2019; 11: 174.

  7. Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med. 2016; 67: 73-89.

  8. Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Molecular Cancer. 2020; 19: 79.

  9. Denkert C, Liedtke C, Tutt A, Minckwitz Gv, Molecular alterations in triple-negative breast cancer the road to new treatment strategies. Breast Cancer. 2017; 389 (10087): P2430-2442.

  10. Kaminskas E, Farrell AT, Wang YC. FDA drug approval summary: azacitidine 5-azacytidine, Vidaza for injectable suspension. Oncologist. 2005; 10: 176-182.

  11. Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020; 383 (7): 650-663.

  12. Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clinical Epigenetics. 2017; 9 (59).

  13. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RWC, Vatapalli1 R et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014; 5: 587-598.

  14. Bradner JE, West N, Grachan M, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010; 6 (3): 238-243.

  15. https://clinicaltrials.gov/ct2/home.

  16. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009; 15 (7): 2488-2496.

  17. Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008; 26 (5): 483-488.

  18. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME et al. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020; 11 (1): 3584.




2020     |     www.medigraphic.com